Adamas Pharmaceuticals Inc (ADMS) Stock Overview
USA - NASDAQ:ADMS - Common Stock
ADMS Key Statistics, Chart & Performance
The current stock price of ADMS is 8.22 null. In the past month the price increased by 1.86%. In the past year, price increased by 84.72%.
ADMS Latest News, Press Relases and Analysis
ADMS Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 21.53 | 402.76B | ||
| AMGN | AMGEN INC | 13.38 | 157.07B | ||
| GILD | GILEAD SCIENCES INC | 15.63 | 150.06B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.88 | 108.04B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.66 | 61.26B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 60.75B | ||
| ARGX | ARGENX SE - ADR | 88.74 | 50.32B | ||
| ONC | BEONE MEDICINES LTD-ADR | 5.02 | 34.14B | ||
| INSM | INSMED INC | N/A | 33.75B | ||
| NTRA | NATERA INC | N/A | 26.42B | ||
| BNTX | BIONTECH SE-ADR | N/A | 25.40B | ||
| BIIB | BIOGEN INC | 9.36 | 21.98B |
Related stock screener links
About ADMS
Company Profile
Adamas Pharmaceuticals, Inc. engages in discovery and development of chrono-synchronous therapies for chronic neurologic disorders. The company is headquartered in Emeryville, California and currently employs 138 full-time employees. The company went IPO on 2014-04-10. The firm is engaged in drug discovery, development and commercialization to deliver medicines for patients, caregivers, and society. The Company’s portfolio product GOCOVRI (amantadine) extended release capsules is used for the treatment of dyskinesia in patients with Parkinson’s disease. Its OSMOLEX ER (amantadine) extended-release tablets is used for the treatment for Parkinson’s disease and drug-induced extrapyramidal reactions in adult patients. Its ADS-5102 is in development for the treatment of walking impairment in patients with multiple sclerosis (MSW). Its product candidate ADS-4101 (lacosamide) modified release capsules is in development for the treatment of partial onset seizures in patients with epilepsy. Its Namzaric (memantine hydrochloride extended release and donepezil hydrochloride) capsules are used for the treatment of dementia of an Alzheimer’s type.
Company Info
Adamas Pharmaceuticals Inc
1900 Powell St Ste 1000
Emeryville CALIFORNIA 94608 US
CEO: Neil F. McFarlane
Employees: 138
Phone: 15104503554.0
Adamas Pharmaceuticals Inc / ADMS FAQ
What does ADMS do?
Adamas Pharmaceuticals, Inc. engages in discovery and development of chrono-synchronous therapies for chronic neurologic disorders. The company is headquartered in Emeryville, California and currently employs 138 full-time employees. The company went IPO on 2014-04-10. The firm is engaged in drug discovery, development and commercialization to deliver medicines for patients, caregivers, and society. The Company’s portfolio product GOCOVRI (amantadine) extended release capsules is used for the treatment of dyskinesia in patients with Parkinson’s disease. Its OSMOLEX ER (amantadine) extended-release tablets is used for the treatment for Parkinson’s disease and drug-induced extrapyramidal reactions in adult patients. Its ADS-5102 is in development for the treatment of walking impairment in patients with multiple sclerosis (MSW). Its product candidate ADS-4101 (lacosamide) modified release capsules is in development for the treatment of partial onset seizures in patients with epilepsy. Its Namzaric (memantine hydrochloride extended release and donepezil hydrochloride) capsules are used for the treatment of dementia of an Alzheimer’s type.
What is the stock price of Adamas Pharmaceuticals Inc today?
The current stock price of ADMS is 8.22 null. The price increased by 0.74% in the last trading session.
Does ADMS stock pay dividends?
ADMS does not pay a dividend.
How is the ChartMill rating for Adamas Pharmaceuticals Inc?
ADMS has a ChartMill Technical rating of 8 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
What is the employee count for ADMS stock?
Adamas Pharmaceuticals Inc (ADMS) currently has 138 employees.
What is Adamas Pharmaceuticals Inc worth?
Adamas Pharmaceuticals Inc (ADMS) has a market capitalization of 374.98M null. This makes ADMS a Small Cap stock.
What is the ownership structure of Adamas Pharmaceuticals Inc (ADMS)?
You can find the ownership structure of Adamas Pharmaceuticals Inc (ADMS) on the Ownership tab.
ADMS Technical Analysis
ChartMill assigns a technical rating of 8 / 10 to ADMS. When comparing the yearly performance of all stocks, ADMS is one of the better performing stocks in the market, outperforming 97.7% of all stocks.
ADMS Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to ADMS. While ADMS seems to be doing ok healthwise, there are quite some concerns on its profitability.
ADMS Financial Highlights
Over the last trailing twelve months ADMS reported a non-GAAP Earnings per Share(EPS) of -2.02. The EPS increased by 46.84% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | -71.1% | ||
| ROA | -43.55% | ||
| ROE | N/A | ||
| Debt/Equity | -5.76 |
ADMS Forecast & Estimates
14 analysts have analysed ADMS and the average price target is 8.69 null. This implies a price increase of 5.72% is expected in the next year compared to the current price of 8.22.
For the next year, analysts expect an EPS growth of 48.66% and a revenue growth 26.58% for ADMS